Lane R

References (18)

Title : BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline - Lane_2009_Mov.Disord_24_392
Author(s) : Lane R , He Y , Morris C , Leverenz JB , Emre M , Ballard C
Ref : Movement Disordersord , 24 :392 , 2009
Abstract : Lane_2009_Mov.Disord_24_392
ESTHER : Lane_2009_Mov.Disord_24_392
PubMedSearch : Lane_2009_Mov.Disord_24_392
PubMedID: 19006190

Title : Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease - Venneri_2009_Neuroreport_20_285
Author(s) : Venneri A , Lane R
Ref : Neuroreport , 20 :285 , 2009
Abstract : Venneri_2009_Neuroreport_20_285
ESTHER : Venneri_2009_Neuroreport_20_285
PubMedSearch : Venneri_2009_Neuroreport_20_285
PubMedID: 19444953

Title : Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients - Nordberg_2009_Curr.Alzheimer.Res_6_4
Author(s) : Nordberg A , Darreh-Shori T , Peskind E , Soininen H , Mousavi M , Eagle G , Lane R
Ref : Curr Alzheimer Res , 6 :4 , 2009
Abstract : Nordberg_2009_Curr.Alzheimer.Res_6_4
ESTHER : Nordberg_2009_Curr.Alzheimer.Res_6_4
PubMedSearch : Nordberg_2009_Curr.Alzheimer.Res_6_4
PubMedID: 19199870

Title : Cholinesterase inhibition: is there evidence for disease-modifying effects? - Shanks_2009_Curr.Med.Res.Opin_25_2439
Author(s) : Shanks M , Kivipelto M , Bullock R , Lane R
Ref : Curr Med Res Opin , 25 :2439 , 2009
Abstract : Shanks_2009_Curr.Med.Res.Opin_25_2439
ESTHER : Shanks_2009_Curr.Med.Res.Opin_25_2439
PubMedSearch : Shanks_2009_Curr.Med.Res.Opin_25_2439
PubMedID: 19678754

Title : Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease - Lane_2008_Pharmacogenet.Genomics_18_289
Author(s) : Lane R , Feldman HH , Meyer J , He Y , Ferris SH , Nordberg A , Darreh-Shori T , Soininen H , Pirttila T , Farlow MR , Sfikas N , Ballard C , Greig NH
Ref : Pharmacogenet Genomics , 18 :289 , 2008
Abstract : Lane_2008_Pharmacogenet.Genomics_18_289
ESTHER : Lane_2008_Pharmacogenet.Genomics_18_289
PubMedSearch : Lane_2008_Pharmacogenet.Genomics_18_289
PubMedID: 18334913

Title : Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study - Ballard_2008_Curr.Med.Res.Opin_24_2561
Author(s) : Ballard C , Sauter M , Scheltens P , He Y , Barkhof F , van Straaten EC , van der Flier WM , Hsu C , Wu S , Lane R
Ref : Curr Med Res Opin , 24 :2561 , 2008
Abstract : Ballard_2008_Curr.Med.Res.Opin_24_2561
ESTHER : Ballard_2008_Curr.Med.Res.Opin_24_2561
PubMedSearch : Ballard_2008_Curr.Med.Res.Opin_24_2561
PubMedID: 18674411

Title : IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease - Winblad_2007_Neurology_69_S14
Author(s) : Winblad B , Grossberg G , Frolich L , Farlow M , Zechner S , Nagel J , Lane R
Ref : Neurology , 69 :S14 , 2007
Abstract : Winblad_2007_Neurology_69_S14
ESTHER : Winblad_2007_Neurology_69_S14
PubMedSearch : Winblad_2007_Neurology_69_S14
PubMedID: 17646619

Title : Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease - Blesa_2007_Neurology_69_S23
Author(s) : Blesa R , Ballard C , Orgogozo JM , Lane R , Thomas SK
Ref : Neurology , 69 :S23 , 2007
Abstract : Blesa_2007_Neurology_69_S23
ESTHER : Blesa_2007_Neurology_69_S23
PubMedSearch : Blesa_2007_Neurology_69_S23
PubMedID: 17646620

Title : Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase - Bullock_2007_Curr.Alzheimer.Res_4_277
Author(s) : Bullock R , Lane R
Ref : Curr Alzheimer Res , 4 :277 , 2007
Abstract : Bullock_2007_Curr.Alzheimer.Res_4_277
ESTHER : Bullock_2007_Curr.Alzheimer.Res_4_277
PubMedSearch : Bullock_2007_Curr.Alzheimer.Res_4_277
PubMedID: 17627485

Title : Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease - Blesa_2006_Pharmacogenet.Genomics_16_771
Author(s) : Blesa R , Bullock R , He Y , Bergman H , Gambina G , Meyer J , Rapatz G , Nagel J , Lane R
Ref : Pharmacogenet Genomics , 16 :771 , 2006
Abstract : Blesa_2006_Pharmacogenet.Genomics_16_771
ESTHER : Blesa_2006_Pharmacogenet.Genomics_16_771
PubMedSearch : Blesa_2006_Pharmacogenet.Genomics_16_771
PubMedID: 17047484

Title : Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease - Burn_2006_Mov.Disord_21_1899
Author(s) : Burn D , Emre M , McKeith I , De Deyn PP , Aarsland D , Hsu C , Lane R
Ref : Movement Disordersord , 21 :1899 , 2006
Abstract : Burn_2006_Mov.Disord_21_1899
ESTHER : Burn_2006_Mov.Disord_21_1899
PubMedSearch : Burn_2006_Mov.Disord_21_1899
PubMedID: 16960863

Title : Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias - Ballard_2006_Int.J.Clin.Pract_60_639
Author(s) : Ballard C , Lane R , Barone P , Ferrara R , Tekin S
Ref : Int J Clin Pract , 60 :639 , 2006
Abstract : Ballard_2006_Int.J.Clin.Pract_60_639
ESTHER : Ballard_2006_Int.J.Clin.Pract_60_639
PubMedSearch : Ballard_2006_Int.J.Clin.Pract_60_639
PubMedID: 16805745

Title : Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease - Bullock_2006_Curr.Med.Res.Opin_22_483
Author(s) : Bullock R , Bergman H , Touchon J , Gambina G , He Y , Nagel J , Lane R
Ref : Curr Med Res Opin , 22 :483 , 2006
Abstract : Bullock_2006_Curr.Med.Res.Opin_22_483
ESTHER : Bullock_2006_Curr.Med.Res.Opin_22_483
PubMedSearch : Bullock_2006_Curr.Med.Res.Opin_22_483
PubMedID: 16574032

Title : Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study - Poewe_2006_Mov.Disord_21_456
Author(s) : Poewe W , Wolters E , Emre M , Onofrj M , Hsu C , Tekin S , Lane R
Ref : Movement Disordersord , 21 :456 , 2006
Abstract : Poewe_2006_Mov.Disord_21_456
ESTHER : Poewe_2006_Mov.Disord_21_456
PubMedSearch : Poewe_2006_Mov.Disord_21_456
PubMedID: 16229010

Title : Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period - Bullock_2005_Curr.Med.Res.Opin_21_1317
Author(s) : Bullock R , Touchon J , Bergman H , Gambina G , He Y , Rapatz G , Nagel J , Lane R
Ref : Curr Med Res Opin , 21 :1317 , 2005
Abstract : Bullock_2005_Curr.Med.Res.Opin_21_1317
ESTHER : Bullock_2005_Curr.Med.Res.Opin_21_1317
PubMedSearch : Bullock_2005_Curr.Med.Res.Opin_21_1317
PubMedID: 16083542

Title : Rivastigmine for dementia associated with Parkinson's disease - Emre_2004_N.Engl.J.Med_351_2509
Author(s) : Emre M , Aarsland D , Albanese A , Byrne EJ , Deuschl G , De Deyn PP , Durif F , Kulisevsky J , van Laar T , Lees A , Poewe W , Robillard A , Rosa MM , Wolters E , Quarg P , Tekin S , Lane R
Ref : N Engl J Med , 351 :2509 , 2004
Abstract : Emre_2004_N.Engl.J.Med_351_2509
ESTHER : Emre_2004_N.Engl.J.Med_351_2509
PubMedSearch : Emre_2004_N.Engl.J.Med_351_2509
PubMedID: 15590953

Title : Rivastigmine in vascular dementia - Vincent_2003_Int.Psychogeriatr_15 Suppl 1_201
Author(s) : Vincent S , Lane R
Ref : Int Psychogeriatr , 15 Suppl 1 :201 , 2003
Abstract : Vincent_2003_Int.Psychogeriatr_15 Suppl 1_201
ESTHER : Vincent_2003_Int.Psychogeriatr_15 Suppl 1_201
PubMedSearch : Vincent_2003_Int.Psychogeriatr_15 Suppl 1_201
PubMedID: 16191241

Title : Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains - Erkinjuntti_2003_Int.J.Clin.Pract_57_756
Author(s) : Erkinjuntti T , Skoog I , Lane R , Andrews C
Ref : Int J Clin Pract , 57 :756 , 2003
Abstract : Erkinjuntti_2003_Int.J.Clin.Pract_57_756
ESTHER : Erkinjuntti_2003_Int.J.Clin.Pract_57_756
PubMedSearch : Erkinjuntti_2003_Int.J.Clin.Pract_57_756
PubMedID: 14686563